Adjuvant ovarian function suppression and cognitive function in women with breast cancer.

Details

Ressource 1Download: 27092785_BIB_6782EAEE877A.pdf (249.14 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_6782EAEE877A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Journal
British journal of cancer
Author(s)
Phillips K.A., Regan M.M., Ribi K., Francis P.A., Puglisi F., Bellet M., Spazzapan S., Karlsson P., Budman D.R., Zaman K., Abdi E.A., Domchek S.M., Feng Y., Price K.N., Coates A.S., Gelber R.D., Maruff P., Boyle F., Forbes J.F., Ahles T., Fleming G.F., Bernhard J.
ISSN
1532-1827 (Electronic)
ISSN-L
0007-0920
Publication state
Published
Issued date
26/04/2016
Peer-reviewed
Oui
Volume
114
Number
9
Pages
956-964
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
To examine the effect on cognitive function of adjuvant ovarian function suppression (OFS) for breast cancer.
The Suppression of Ovarian Function (SOFT) trial randomised premenopausal women with hormone receptor-positive breast cancer to 5 years adjuvant endocrine therapy with tamoxifen+OFS, exemestane+OFS or tamoxifen alone. The Co-SOFT substudy assessed objective cognitive function and patient reported outcomes at randomisation (T0), and 1 year later (T1); the primary endpoint was change in global cognitive function, measured by the composite objective cognitive function score. Data were compared for the pooled tamoxifen+OFS and exemestane+OFS groups vs the tamoxifen alone group using the Wilcoxon rank-sum test.
Of 86 participants, 74 underwent both T0 and T1 cognitive testing; 54 randomised to OFS+ either tamoxifen (28) or exemestane (26) and 20 randomised to tamoxifen alone. There was no significant difference in the changes in the composite cognitive function scores between the OFS+ tamoxifen or exemestane groups and the tamoxifen group (mean±s.d., -0.21±0.92 vs -0.04±0.49, respectively, P=0.71, effect size=-0.20), regardless of prior chemotherapy status, and adjusting for baseline characteristics.
The Co-SOFT study, although limited by small samples size, provides no evidence that adding OFS to adjuvant oral endocrine therapy substantially affects global cognitive function.

Keywords
Adjuvants, Immunologic, Adult, Antineoplastic Agents, Hormonal/therapeutic use, Breast Neoplasms/complications, Breast Neoplasms/drug therapy, Cognition, Female, Humans, Middle Aged, Ovary/metabolism, Premenopause, Quality of Life, Tamoxifen/therapeutic use
Pubmed
Open Access
Yes
Create date
03/05/2016 16:31
Last modification date
20/08/2019 14:23
Usage data